100例乳腺癌雌激素和孕激素受体的测定和分析

对100例乳腺癌选用ER和PR抗血清,采用ABC法进行免疫组化染色,结果发现:ER和PR同时阳性者为40例(40％),ER和PR同时阴性者为26例(26％);所有病例随访3～4年,40例ER和PR同时阳性中有1例复发,占2.5％,26例ER和PR同时阴性中有12例复发,占46.2％,二者有显著差异性(P<0.01)。结果提示:乳腺癌ER和PR同时阳性病预后较阴性病例好,因此,同时测定乳腺癌ER和PR对临床制定乳腺癌的治疗方案和判定预后有重大价值和意义。     

乳腺癌雌激素受体和孕激素受体二种检测方法的比较研究

乳腺癌是当前危害妇女生命健康的最常见恶性肿瘤之一。为了提高乳腺癌患者生存率,测定乳腺癌组织中ER和PR水平已被作为制定治疗计划和评估预后的主要依据,近年来正日益受到临床医师的重视和关注。迄今为止国内已有不少实验室开展了ER和PR的检测分析,而且测定的方法也较     

人体乳腺癌雌激素和孕激素受体检测75例分析

雌激素受体(ER)和孕激素受体(PgR)的检测已广泛应用于临床。本文用ABC法(Avidin-BiotinComplex method)标记了75例乳腺癌石蜡切片,并结合临床资料对标记结果进行分析,旨在探讨ER、PgR免疫组化测定的临床意义。     

乳腺癌超声征象与雌激素受体、孕激素受体及C-erbB-2表达的相关性分析

目的 探讨乳腺癌超声征象与雌激素受体(ER)、孕激素受体(PR)及C-erbB-2表达的相关性.方法 选取的82例乳腺癌患者均接受超声检查,观察肿瘤大小、分级、类型、淋巴结转移及脉管侵犯情况等;免疫组化法检测乳腺癌患者乳腺癌组织中ER、PR及C-erbB-2的阳性表达率,并分析不同超声征象与ER、PR及C-erbB-2...     

C—erbB—2癌基因与雌激素和孕激素受体在乳腺癌中的对比研究

采用ＡＢＣ免疫组化染色对２００例乳腺癌进行Ｃ－ｅｒｂＢ－２，ＥＲ和ＰＲ测定，结果发现：（１）ＥＲ阳性１１２例中Ｃ－ｅｒｂＢ－２阳性１８例（１６．１％），ＥＲ阴性８８例中Ｃ－，ｅｒｂＢ－２阳性５７例（６４．８％）；ＰＲ阳性１０２例中Ｃ－ｅｒｂＢ－２阳性１６例（１５．７％），ＰＲ阴性９８例中Ｃ－ｅｒｂＢ－２阳性５９例（６０．２％）；（２）Ｃ－ｅｒｂＢ－２阳性率与肿瘤大小和淋巴结转移有关，随访４年以上。     

乳腺癌雌激素受体孕激素受体和C-erbB-2癌基因蛋白表达的临床意义

目的研究乳腺癌中雌、孕激素受体(ER,PR)与C,erbB-2癌基因的表达情况及临床意义。方法应用免疫组化S.P法,对82例原发性乳腺癌组织进行了ER,PR和C/erbB02检测,并进行统计学分析。结果ER,PR和C1erbB22的表达率分别为54.9%,40.2%,47.6%。ER的表达与C3erbB42的表达呈显著负相关(P<0.01)。C5erbB62的表达与肿瘤体积呈显著正相关(P<0.01),与年龄、组织学类型和淋巴结转移无明显相关性(P>0.05)。结论ER,PR的阳性表达是乳腺癌预后良好的指标,C7erbB82是乳腺癌预后不良的指标。ER,PR和C9erbB:2的测定对乳腺癌的诊断、治疗和预后判断具有重要的指导意义。     

乳腺癌中PS2基因与雌激素及孕激素受体

乳腺癌中ＰＳ２基因与雌激素及孕激素受体阚秀薛卫成乳腺癌激素疗法，最早于１８９６年由Ｂｅａｔｓｏｎ报道。１９６７年Ｊｅｎｓｅｎ发现雌激素受体（ＥｓｔｒｏｇｅｎＲｅｃｅｐｔｏｒ，ＥＲ），其后又发现孕激素受体（ＰｒｏｇｅｓｔｅｒｏｎｅＲｅｃｅｐｔｏｒ，ＰＲ...     

乳腺癌C-erbB-2癌基因与雌激素和孕激素受体的关系及其意义

目的　探讨乳腺癌C -erbB - 2癌基因与雌激素和孕激素受体的关系及其意义。方法　采用免疫组化方法 (二步法 ) ,检测 83例乳腺癌组织中C -erbB - 2、ER、PR的表达。结果　C -erbB - 2、ER、PR在乳腺癌组织中表达阳性率为 5 7 83%、71 0 8%、6 6 2 7%。C -erbB - 2表达 :在ER、PR阴性组高于ER、PR阳性组 (P <0 0 5 ) ;在淋巴结转移组的乳腺癌高于淋巴结未转移组 (P <0 0 5 )。结论　C -erbB - 2与ER、PR联合检测 ,对于乳腺癌患者术后选择个性化化疗具有指导意义 ,也是衡量预后的重要指标。     

Cytosol and nuclear estrogen receptors (occupied and unoccupied sites) and progesterone receptors in human breast cancer

Summary Estrogen and progesterone receptor concentrations in cytosol and nucleus were measured in 21 primary breast cancer tumors. Twelve out of the 21 tumor samples were cytosol estrogen receptor positive, 8 of which contained only unoccupied estrogen binding sites in the cytosol, but 2 of the 9 estrogen receptor negative samples did contain cytosol binding sites already occupied by endogenous homone. Four other estrogen receptor negative tumors only showed nuclear binding sites. Only 3 of the 12 estrogen receptor positive tumors also contained progesterone receptors. All of these tumors also had estrogen receptor in the nucleus. However, three of the 17 progesterone receptor negative samples had progesterone receptor only in the nucleus. The present data indicate that 3 possible classes of false negative tumors can be encountered: 1) estrogen receptors occupied by endogenous hormone, 2) tumors containing only nuclear estrogen receptors, and 3) tumors having only nuclear progesterone receptors. Measurement of nuclear estrogen receptor together with the progesterone receptor provides further information on whether the estrogen receptor system is not only present but also functional, and should be of value in the prediction of hormone dependent breast cancer.     

The effect of tumor size and axillary lymph node metastasis on estrogen and progesterone receptors in primary breast cancer

We evaluated the estrogen receptors (Er) and the progesterone receptors (Pr) in 209 female patients with primary breast cancer. There is statistically a very highly significant negative correlation between the size of the tumor and the Pr (p = 0.007); large tumor contains low Pr. The same correlation was found with Er, but it was not statistically significant (p = 0.40). There is also a negative correlation between the number of axillary metastatic lymph nodes and Er and Pr, but this was not statistically significant.     

Estrogen receptors,progesterone receptors,and cell proliferation in human breast cancer

Summary The breast is a target organ for estrogens and progesterone. These hormones control several functions of the normal and abnormal mammary epithelium including cell proliferation. Most of the actions of estrogens and progesterone are mediated via specific steroid receptors, and one would expect that proliferating cells should contain estrogen receptors (ER) and/or progesterone receptors (PR). However, the correlation between receptor expression and cell proliferation is still controversial. In the present study we have examined 29 human breast cancer samples; in 17 of them we evaluated the simultaneous ER and PR localization with that of proliferating cell nuclear antigen (PCNA) and silver-stained nucleolar organizer regions (AgNORs) in a cell-by-cell study. We found that in almost 50% of the tumor biopsies examined, the cells expressing ER were significantly associated with elevated cell proliferation. In another group (38%) there were not significant differences between ER expression and cell proliferation. In only one of the samples (6%) the cells expressing ER showed lower cell proliferation. The study also revealed that in 44% of the tumors the PR expressing cells were associated with elevated cell proliferation. In a second group the PR expression was not significantly associated with cell proliferation (33% of the cases). Finally, in 22% of the samples the cells carrying PR showed lower cell proliferation. We also detected lower ER immunoreactivity in 30% of the breast cancer biopsies with one of the monoclonal antibodies against ER (antibody 1D5 directed against the A/B domain). This group of tumors was PR-negative (or very weakly positive) and had high proliferation. The presence of tumors with abnormal ER proteins and displaying ER/PR significantly associated with elevated cell proliferation could have implications in human breast cancer treatment.     

Response to primary chemotherapy in breast cancer patients with tumors not expressing estrogen and progesterone receptors

Background:We recently demonstrated that in premenopausalpatients with estrogen receptors (ER)-absent tumors, early initiation ofsystemic chemotherapy after primary surgery might improve outcome. These dataindicate a different responsiveness to chemotherapy for tumors not expressinghormone receptors. To test this hypothesis we evaluated the responsiveness topreoperative chemotherapy in patients with ER and progesterone receptors(PgR)-absent tumors. Patients and methods:Patients with biopsy-provenT₂–T₃, N_0–2 breast cancertreated at a single institution from January 1995 to August 1999 withpreoperative chemotherapy were retrospectively evaluated. ER and PgR weredetermined immunohistochemically and classified for this purpose as absent(0% of the cells positive) or positive (1% of the cells). Results:On 117 evaluable patients 72 had an objective response(61%). A significant difference in response was observed for patientswith ER and PgR absent compared with those with ER and/or PgR-positive tumors(82% vs. 57%,P = 0.03 Fishers's exact test).Pathological complete remission rates were also significantly different in thetwo groups (23% vs. 7%, respectively; P = 0.04). Conclusions:The different degree of response according to hormonereceptors expression supports the hypothesis that tumors not expressing bothER and PgR might represent a different clinical entity in terms ofchemotherapy responsiveness.     

The detection and analysis of estrogen and progesterone receptors in breast cancer (report of 1,393 patients)

Objective To explore the distribution of estrogen receptors (ER) and progesterone receptors (PR) in patients with breast cancer and to compare the results with clinical parameters. Methods Breast cancer specimens of 1393 cases were stained for the ER and PR by a SP Two -Step method, and analyzed with respect to age, menstrual status, histopathology and metastasis of axillary lymph nodes. Results The correlation coefficients between ER and PR were positive-(P< 0.0001). The negative expression of ER in patients 39 years or less was the highest with a statistical significance (P<0.0001 ). There was no relationship between the patient’s age and positive expression of ER, PR and negative expression of PR (P>0.05). There were significantly higher positive rates of ER and lower positive rates of PR in post-menopausaf patients than in pre -menopausal cases(P<0.0001). There was no relationship between the status of ER, PR and the corresponding histopathology (P>0.05). The patients with no metastasis in the axillary lymph nodes had higher simultaneous positive rates of ER and PR (P<0.0001), and those with axillary lymph node metastasis had significantly higher rates of negative expression of ER and PR(P<0.0001). Conclusion The positive and negative distributions of ER and PR have some regular patterns which may be used as a reference to choose combined therapy and to predict the prognosis for breast cancer patients.     

The Detection and Analysis of Estrogen and Progesterone Receptors in Breast Cancer （Report of 1,393 Patients）

Objective  To explore the distribution of estrogen receptors (ER) and progesterone receptors (PR) in patients with breast cancer and to compare the results with clinical parameters. Methods  Breast cancer specimens of 1393 cases were stained for the ER and PR by a SP Two -Step method, and analyzed with respect to age, menstrual status, histopathology and metastasis of axillary lymph nodes. Results  The correlation coefficients between ER and PR were positive-(P< 0.0001). The negative expression of ER in patients 39 years or less was the highest with a statistical significance (P<0.0001 ). There was no relationship between the patient’s age and positive expression of ER, PR and negative expression of PR (P>0.05). There were significantly higher positive rates of ER and lower positive rates of PR in post-menopausaf patients than in pre -menopausal cases(P<0.0001). There was no relationship between the status of ER, PR and the corresponding histopathology (P>0.05). The patients with no metastasis in the axillary lymph nodes had higher simultaneous positive rates of ER and PR (P<0.0001), and those with axillary lymph node metastasis had significantly higher rates of negative expression of ER and PR(P<0.0001). Conclusion  The positive and negative distributions of ER and PR have some regular patterns which may be used as a reference to choose combined therapy and to predict the prognosis for breast cancer patients.     

Impact of low estrogen/progesterone receptor expression on survival outcomes in breast cancers previously classified as triple negative breast cancers

PURPOSE:

To evaluate the impact of low estrogen/progesterone receptor (ER/PR) expression and effect of endocrine therapy on survival outcomes in human epidermal growth factor receptor 2 (HER2)‐negative tumors with ER/PR <10%, previously labeled as triple negative.

METHODS:

In a retrospective review, 1257 patients were categorized according their ER/PR percentages into 3 groups, ER/PR <1% (group A), ER/PR 1% to 5% (group B), and ER/PR 6% to 10% (group C). Kaplan‐Meier product limit method was used to estimate survival outcomes. Cox proportional hazards models was used to adjust for patient and tumor characteristics.

RESULTS

Groups A, B, and C had 897 (71.4%), 241 (19.2%), and 119 (9.4%) patients, respectively. After a median follow‐up of 40 months there was no significant difference in 3‐year recurrence‐free survival (RFS): 64%, 67%, and 77% (P = .34) or overall survival (OS): 79%, 81%, and 88% (P = .33) for groups A, B, and C, respectively. ER/PR expression was not an independent predictor for RFS (hazard ratio [HR], 1.10; 95% confidence interval [CI], 0.86‐1.39; P = .46 for group B, and HR, 0.96; 95% CI, 0.66‐1.38; P = .81 for group C, compared with group A), or OS (HR, 1.11; 95% CI, 0.84‐1.46; P = .46 for group B, and HR, 0.94; 95% CI, 0.63‐1.42; P = .78 for group C, compared with group A). Endocrine therapy had no impact on survival outcomes (RFS: P = .10; OS: P = .45) among groups.

CONCLUSIONS:

In this cohort, a low ER/PR level (1%‐5%) does not appear to have any significant impact on survival outcomes. There was a tendency for survival advantages in the ER/PR 6% to 10% is seen. Benefit of endocrine therapy in these patients is unclear. Cancer 2011;. © 2011 American Cancer Society.     

Colocalization of estrogen and progesterone receptors with an estrogenregulated heat shock protein in paraffin sections of human breast and endometrial cancer tissue

Summary We have studied by immunocytochemistry and monoclonal antibodies the presence and localization of estrogen receptors, progesterone receptors, and a 24-kD estrogen-regulated heat shock protein in biopsies from breast and endometrial cancer patients. Three different tissue processing protocols were used to colocalize the antigens in the same tissue sections: a) frozen sections, b) formalin fixation with routine paraffin embedding, and c) picric acid-formaldehyde (PAF) fixation with a rapid embedding in paraffin. Frozen sections showed good receptor staining but poor 24-kD protein immunoreactivity, while routine paraffin sections (with or without DNase pretreatment) were inadequate to reveal the nuclear receptor proteins at the same level seen in frozen sections. On the other hand, all three proteins could be detected satisfactorily in PAF-fixed paraffin-embedded tissue. Using this procedure we were able to visualize 24-kD protein and estrogen receptor or progesterone receptor in individual cells in paraffin sections. The study revealed that in all of the estrogen receptor positive breast and endometrial tumor samples, almost 90% of the cells expressing the cytoplasmic 24-kD protein contained estrogen receptor in the cell nucleus. In contrast, 24-kD immunoreactive cells did not express progesterone receptors in almost 40% of the progesterone receptor positive tumor samples.     

Presurgical radiotherapy decreases the concentrations of estrogen and progesterone receptors in human breast cancer: A 200-patient study

Summary The concentrations of cytosol estrogen (RE) and progesterone (RP) receptors were evaluated in human breast cancer either pretreated or untreated by radiotherapy. Receptor sites were assayed within a week following surgery by using the classical dextran-coated charcoal technique with three saturating concentrations of (³H) 17 estradiol and (³H) R5020 and by correcting for nonsaturable binding estimated in parallel with an excess of nonradioactive ligand. Only tissue containing cancer cells as determined by a pathologist was assayed for receptors.Two nonrandomised groups were compared: a control group of 91 patients which were not treated before surgery, and an irradiated group of 108 patients which received radiotherapy (60 to 70 grays) about 2 to 4 months before surgery. Radiotherapy significantly reduced the percentage of receptor positive tumors ( 10 fmoles/mg protein) from RE 82% and RP 67% in the control group to RE 54% and RP 28% in the irradiated group.The mean concentrations of the positive receptors were also decreased by irradiation, from 238 fm/mgP and 146 fm/mgP to 55 fm/mgP and 54 fm/mgP for RE and RP respectively. This decrease was observed for all histopathological stages studied in both pre- and postmenopausal patients, and was also not dependent on cell density. Since the irradiated patients mostly had tumors of TNMT₂ and nonirradiated patients had smaller tumors (TNM T₂), we checked that the same effect of radiotherapy was found in the homogeneous group of TNM = T₂.We conclude that presurgical radiotherapy of breast cancer decreases the percentage of estrogen receptor and progestin receptor positive patients. Therefore, the assay of steroid receptors in breast cancer remains useful in predicting hormone dependency and prognosis of breast cancer when receptor concentrations are positive. But the assay is of no value when receptor concentrations are negative. New micro techniques must therefore be developed for assaying receptor before any therapy.